Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

45.4K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling Highlights the Challenge of Achieving and Maintaining Hepatitis C Virus Micro-Elimination Among People Who Inject Drugs.

Open forum infectious diseases·2026
Same author

Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions.

ArXiv·2026
Same author

Rat hepatitis E virus infection has multiphasic viral replication kinetics <i>in vivo</i>.

bioRxiv : the preprint server for biology·2026
Same author

Modeling in vitro cell-to-cell spread of hepatitis C viral infection using an agent-based approach.

bioRxiv : the preprint server for biology·2026
Same author

Early hepatitis B and delta virus kinetics in patients undergoing liver transplantation.

Scientific reports·2026
Same author

Modeling predicts shortening of DAA treatment duration to 5 weeks in individuals with recent or chronic infection with HCV RNA negativity at day 7 on treatment.

The Journal of infectious diseases·2026

Related Experiment Video

Updated: May 12, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.5K

Functional Cure for Hepatitis B Virus: Challenges and Achievements.

Oren Shechter1, Daniel G Sausen2, Harel Dahari3

  • 1Eastern Virginia Medical School, Norfolk, VA 23501, USA.

International Journal of Molecular Sciences
|May 7, 2025
PubMed
Summary

Achieving a functional cure for Hepatitis B Virus (HBV) infection is crucial. This review explores novel strategies beyond current treatments to suppress HBV and HBsAg, reducing disease and transmission.

Keywords:
HBsAgPEG-IFNα therapyfunctional curehepatitis B virus (HBV)immunological markersnucleos(t)ide analog (NA) therapysiRNA therapytherapeutic vaccine

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.0K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.1K

Related Experiment Videos

Last Updated: May 12, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.5K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.0K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.1K

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis B Virus (HBV) infection affects millions globally, causing significant health burdens.
  • Chronic HBV infection is difficult to treat due to viral evasion of immune responses and lack of curative therapies.
  • Current antiviral treatments suppress HBV but do not eliminate the virus or achieve a cure.

Purpose of the Study:

  • To review the concept and immunological basis of a functional cure for Hepatitis B Virus (HBV).
  • To explore emerging therapeutic strategies aimed at achieving a functional cure for HBV.
  • To highlight the need for innovative approaches to manage chronic HBV infection.

Main Methods:

  • Literature review of HBV epidemiology, clinical impact, and current treatment limitations.
  • Discussion of the immunological mechanisms underlying a functional cure for HBV.
  • Analysis of novel therapeutic modalities including RNA interference, entry inhibitors, nucleic acid polymers, and therapeutic vaccines.

Main Results:

  • A functional cure for HBV involves suppressing viral replication and HBsAg, mitigating disease progression and transmission.
  • Emerging therapies show promise in achieving a functional cure by targeting different stages of the HBV lifecycle and immune modulation.
  • Significant challenges remain in developing curative strategies due to HBV's complex biology and immune evasion tactics.

Conclusions:

  • A functional cure for HBV is an attainable goal that requires innovative therapeutic strategies.
  • Further research into novel agents and combination therapies is essential to overcome the limitations of current treatments.
  • Achieving a functional cure will significantly reduce the global burden of Hepatitis B Virus infection.